MORGAN STANLEY

Holdings History for Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share (TSHA)

Symbol: TSHA on Nasdaq
Investment type: Equity / Common Stock, par value $0.00001 per share
Latest Disclosed Shares Owned: 16,858,644 shares
Security Ownership %: 6.7%

Shares, Excluding Options vs Price

Value, Excluding Options

Morgan Stanley ownership in Taysha Gene Therapies, Inc. Common Stock, par value $0.00001 per share (TSHA)

06 Aug 2025 - Morgan Stanley has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 16,858,644 shares of Taysha Gene Therapies, Inc. Common Stock, par value $0.00001 per share (TSHA). This represents 6.7% ownership of the company. In their previous filing dated 05 Feb 2025, MORGAN STANLEY had reported owning 17,629,264 shares, indicating a decrease of +4.4%. .

Reporting Name	Ownership %	Change	Value $	Shares owned	Change	Activity %	Price	Form	Report date	Filing time
Morgan Stanley	6.7%	-21%	$44,506,820	16,858,644	-770,620	-4.4%	$2.64	13G/A	30 Jun 2025	06 Aug 2025, 14:13
Morgan Stanley	8.6%		$32,085,260	17,629,264			$1.82	13G	31 Dec 2024	05 Feb 2025, 10:43

Holdings date	Weight	Change	Value $	Shares	Change	Activity %	Price	All Holders
31 Dec 2025	0.01%	-0%	$99,431,850	18,078,518	-1,229,085	-6.4%	$5.50	Q4 2025
30 Sep 2025	0%	+0%	$63,135,862	19,307,603	+2,442,521	+14%	$3.27	Q3 2025
30 Jun 2025	0%	+0%	$38,958,339	16,865,082	+18,708	+0.11%	$2.31	Q2 2025
31 Mar 2025	0%	-0%	$23,416,461	16,846,374	-793,992		$1.39	Q1 2025
31 Dec 2024	0%	+0%	$30,517,834	17,640,366	+9,976,373	+100%	$1.73	Q4 2024
30 Sep 2024	0%	+0%	$15,404,626	7,663,993	+186,596		$2.01	Q3 2024
30 Jun 2024	0%	+0%	$16,749,369	7,477,397	+2,308,507		$2.24	Q2 2024
31 Mar 2024	0%	+0%	$14,834,714	5,168,890	+4,952,352	+2287%	$2.87	Q1 2024
31 Dec 2023	0%	+0%	$383,272	216,538	+44,469	+26%	$1.77	Q4 2023
30 Sep 2023	0%	+0%	$543,739	172,069	+40,761	+31%	$3.16	Q3 2023
30 Jun 2023	0%	+0%	$86,794	131,308	+43,495	+50%	$0.66	Q2 2023
31 Mar 2023	0%	+0%	$70,039	87,813	+64,206	+272%	$0.80	Q1 2023
31 Dec 2022	0%	0%	$53,352	23,607	-1,334	-5.3%	$2.26	Q4 2022
30 Sep 2022	0%	-0%	$48,000	24,941	-45,839	-65%	$1.92	Q3 2022
30 Jun 2022	0%	-0%	$263,000	70,780	-104,897	-60%	$3.72	Q2 2022
30 Jun 2022		0%	$2,000	793	0		$2.52 ^*	Q2 2022
31 Mar 2022	0%	+0%	$1,147,000	175,677	+33,367	+23%	$6.53	Q1 2022
31 Mar 2022		0%	$1,000	78	0		$12.82 ^*	Q1 2022
31 Dec 2021	0%	+0%	$1,658,000	142,310	+17,251	+14%	$11.65	Q4 2021
30 Sep 2021	0%	+0%	$2,328,000	125,059	+89,027	+247%	$18.62	Q3 2021
30 Jun 2021	0%	+0%	$764,000	36,032	+13,071	+57%	$21.20	Q2 2021
30 Jun 2021		0%	$2,000	74	0		$27.03 ^*	Q2 2021
31 Mar 2021	0%	-0%	$466,000	22,961	-8,377	-27%	$20.30	Q1 2021
31 Dec 2020	0%	+0%	$832,000	31,338	+31,338	NEW	$26.55	Q4 2020

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.